4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$24.80 USD
+0.07 (0.28%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $24.82 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
4D Molecular Therapeutics, Inc. [FDMT]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Focusing on 4D-150 - Directed Evolution Platform Continues Vector Progress; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Interpreting Recent Gene Therapy Advancements in Wet AMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Interim 4D-310 Update Supportive of Vector Platform - Next Steps Immunosuppressive Regimen
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Positive PRISM Trial Interim-Robust 4D-150 Annualized Anti-VEGF Reduction; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for FDMT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Diversified Progress Across Directed Evolution Gene Therapy Pipeline; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Boots on the Ground at AAO?23-KOL Perspectives and Considerations on Therapeutic Ophthalmic Innovations
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Positive Phase 1/2 AEROW Interim Data Supportive of 4D-710 Progress in CF; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Gene Therapy Progress Across Platform-Focusing on Retina and CF; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Additional Phase 1/2 PRISM Data at ASRS ?23 Support Consistent 4D-150 Profile; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Views on Clinical Progress in the Retina-Highlights From Clinical Trials at the Summit 2023 Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Positive Interim 4D-710 Phase 1/2 Update-Tailwinds for CF Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Phase 1/2 PRISM Trial Paves Path Forward for 4D-150, Broader Pipeline Progress; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Positive Phase 1/2 PRISM Data in wAMD Support 4D-150 Advancement; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
2023 Clinical Progress Across Directed Evolution Platform; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Overcoming aHUS-4D-310 Strategy Bolstered By Interim Phase 1/2 Update; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Near-Term FDA Feedback Expected on 4D-310, Independent of 4D-150 Progress; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: 4D Molecular Therapeutics, Inc.
Industry: Medical - Drugs
Evolving With Directed Evolution in wAMD and Broader Systemic Potential; Initiating With Buy Rating and $36 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
|